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ABSTRACT The hydroxamic acid siderophore ferrioxam-
ine B [Fe"'(HDFB)+] and the iron complex of diethylenetri-
aminepentaacetic acid [FeI"(DTPA)2i] protected mice
against death by septic shock induced by Corynebacterium
parvum + lipopolysaccharide. Although Fem(DTPA)2- was
somewhat more effective than FeI"(HDFB)+, the iron-free
ligand H4DFB+ was significantly more effective than DTPA.
The hydroxamic acid chelator has a much higher iron affinity
than the amine carboxylate, allowing for more efficient for-
mation of the FeI"(HDFB)+ complex upon administration of
the iron-free ligand. Electrochemical studies show that FeIII-
(DTPA)2- binds NO stoichiometrically upon reduction to
iron(II) at biologically relevant potentials to form a stable NO
adduct. In contrast, FeI"I(HDFB)+ is a stable and efficient
electrocatalyst for the reduction ofNO to N20 at biologically
relevant potentials. These results suggest that the mechanism
of protection against death by septic shock involves NO
scavenging and that particularly effective drugs that operate
a low dosages may be designed based on the principle of redox
catalysis. These complexes constitute a new family of drugs
that rely on the special ability of transition metals to activate
small molecules. In addition, the wealth of information avail-
able on siderophore chemistry and biology provides an intel-
lectual platform for further development.
Nitric oxide (NO), a short-lived potent vasodilator, was first
described as the endothelium-derived relaxation factor
(EDRF) (1-3). The formation of NO from the guanidino
nitrogen group of L-arginine is catalyzed by a group of enzymes
termed constitutive (cNOs) and inducible (iNOs) NO syn-
thases (3, 4). The inducible form is not present constitutively
in mammalian cells but is induced by proinflammatory stimuli
such as bacterial lipopolysaccharide (LPS), Corynebacterium
parvum, and the cytokines tumor necrosis factor-a, interleu-
kin-1, or interferon-y, individually or in combination (5).
Excess production ofNO is reported to be associated with the
development of hypotension associated with endotoxemia and
sepsis (6-8).
Inhibition of iNOs is a potential therapeutic approach to the
treatment of septic shock (6-9). However, mechanisms to
protect against the deleterious effects of NO overproduction
constitute an alternative approach. For instance, free hemo-
globin can scavenge NO and inhibit its biological effects (10).
In LPS-treated mice, formation of a paramagnetic mononitrosyl
iron complex with diethyldithiocarbamate (NO Fe DETC) was
detected and characterized by electron paramagnetic reso-
nance (11). The NO formed in this animal model was trapped
with endogenous Fe2+ complexed with a considerable amount
(500 mg/kg) of DETC that was administered to the animals
during the course of the experiment (11). Mortality was not
addressed in this study. On the other hand, administration of
vitamin B12A to mice prevented and reversed endotoxin-
mediated hypotension and decreased mortality, possibly
through binding of the vitamin with excess NO (12). Inhibition
of several actions of NO, including protection of rats against
endotoxin, was demonstrated with the NO scavenger 2-phenyl-
4,4,5,5-tetramethylimidazolineoxyl-i-oxyl 3-oxide (13). We
and others have characterized the in vivo models of induction
of iNOs in mice and rats injected with C. parvum or C. parvum
+ LPS (14-18). We postulated that iron complexes could act
as general NO scavengers and provide protection against septic
shock. We screened a library of metal chelators and chelates
and found that [Fe(III)(H2DTPA)] and [Fe(III)(HDFB)]+
(Fig. 1, 4 and 2, respectively) offered the highest mortality
decrease in an experimental model of septic shock (19). We
determined that the Fe(II) form of both complexes can bind
NO, which we believe is related to their biological function.
MATERIALS AND METHODS
Materials. The ferrioxamine B complex 2 was prepared by
reacting deferoxamine mesylate (Sigma) and ammonium
iron(III) sulfate dodecahydrate (Aldrich) in 1:10 molar ratio in
water. The resulting complex 2 was desalted on C18 reversed
phase high performance liquid chromatography (Vydac
218TP1022) using 0-20% B gradient versus A (B: 0.1% TFA
in acetonitrile; A: 0.1% TFA in water) over 30 min. The
fraction was collected and lyophilized. Correct MS (FAB) and
C, H, N, Fe, F data were obtained for 2 containing two
molecules of TFA. Iron diethylenetriamminepentaacetic acid
(DTPA), disodium salt dihydrate, 3 was used as packaged by
Aldrich.
C. parvum + LPS Shock. Male CD-1 mice, 18-22 g (Charles
River Breeding Laboratories), are injected i.v. with 100 mg of
killed C. parvum (Coparvax, Burroughs Wellcome). Ten days
later, the mice are injected i.v. with 20 mg of Escherichia coli
026:B6 LPS (Difco) in the presence of the analgesic butor-
phanol (150 mg per mouse). Compounds are dissolved in saline
for i.v. dosing 2 h before and at the same time as or 30 min after
the LPS. Control (non-drug-treated) animals go into shock
within the first 90 min following LPS administration, and
approximately 90% die within 5 h. Mice are monitored for the
first 7 h and at 24 and 48 h for survival. All animal use
procedures were approved by an Institutional Animal Care
and Use Committee and were designed to conform to the
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constitutive NO synthase; iNOs, inducible NO synthase; LPS, lipo-
polysaccharide; DETC, diethyldithiocarbamate; DTPA, diethylenetri-
aminepentaacetic acid; DTPA iron complex, [Fe(III)(H2DTPA)] (4);
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FiG. 1. Structures of desferal 1, DTPA 3, and their iron(III)
complexes 2 and 4, respectively.
Guide for the Care and Use of Laboratory Animals (National
Institutes of Health Publication 86-23, 1985).
Electrochemistry. Phosphate buffers were prepared at 0.5
M concentrations using Na2HPO4 (Fisher) and KH2PO4 (EM
Science) dissolved in Milli-Q water. Solutions were degassed
using purified N2 or argon gas. NO (Matheson, 99.0% pure)
and NaNO2 (EM Science) were used without further purifi-
cation. Electrochemistry was performed using a Princeton
Applied Research model 273A potentiostat and Princeton
Applied Research model 270/250 analysis software. Cyclic
voltammetry was conducted using a conventional three-
compartment cell with ports for degassing solutions/addition
of substrate in which a Bioanalytic Systems glassy carbon
electrode was used as the working electrode. The auxiliary
compartment contained a platinum wire auxiliary electrode
separated from the main compartment by a medium glass frit.
Cell potentials were measured using a sodium chloride-
saturated calomel electrode as a reference. Controled-
potential coulometry was performed using a vitreous carbon
working electrode with a Pt gauze auxiliary. Gas analysis for
NO and N20 was performed using a Hewlett Packard model
5890A gas chromatograph with a thermal conductivity detec-
tor on a Hewlett-Packard 6-ft s-A 60/80 mesh molecular sieve
column with helium carrier gas.
RESULTS AND DISCUSSION
Protective Effects of Iron Chelators in Experimental Septic
Shock Iron complexes are capable of forming relatively stable
NO adducts (20-23). In a search for alternative approaches to
septic shock therapy, we postulated that metal complexes, and
in particular iron chelators, could act as "molecular sponges,"
mopping up the excess NO produced during septic shock. To
identify lead compounds that would protect against septic
shock, we screened a library of metal chelators in the C.
parvum + LPS murine model of septic shock (19). Injection of
mice with killed C. parvum followed 10 days later by LPS
resulted in 100% mortality within 48 h (Table 1). Approxi-
mately 50% of mice were alive 2.5-3 h after LPS injection (a
reflection of how acute the response to LPS is) and 90-95%
mortality was reached within 5 h (Table 1). The compounds
were evaluated at 0.1, 1.0, 10, and 40 mg/kg. We found that
maximum protection against septic shock was offered by both
2 and 4 (Fig. 1) when administered at 10 mg/kg (19), Table 1.
Survival was greatly enhanced by the administration of 4 or
2 either 2 h before and at the time of or 30 min after LPS. In
contrast, the Fe3+-free ligands of these compounds, 3 and 1,
were less protective when administered before and at the time
of LPS and virtually ineffective when administered after LPS.
The clear advantage of 4 over 2 when administered after LPS
was observed over a large number of experiments [76%
survival with 4 (n = 102 mice) and 38% survival with 2 (n =
64 mice)].
The free ligand 1 was more protective than 3. This difference
probably results from the greater facility with which 1 seques-
ters iron (24-27). As a result, the differ4nce in protective
Table 1. Treatment of C. parvum + LPS-induced septic shock
in mice
Dose,t Dose schedule, % alivet
Compound* mg/kg h 5 h 48 h
1 10 -2.0 and 0 80 40
+0.5 60 15
2 10 -2.0 and 0 100 65
+0.5 60 50
3 10 -2.0 and 0 95 45
+0.5 5 0
4 10 -2.0 and 0 95 70
+0.5 85 75
Saline -2.0 and 0 10 0
+0.5 5 0
*Compounds identified in Fig. 1
tCompounds dosed iv in saline 2 h before and at the time of LPS or
0.5 h after LPS.
:n = 20.
properties of 1 relative to 2 at 30 min were much less dramatic
than those for 3 and 4, respectively. Compound 3 has a lower
affinity and selectivity for iron than 1; when administered at 30
min, 3 lacked any protective properties. On the other hand its
administration at -2.0 and 0 h provided enough time for 3 to
sequester iron and to be effective (Table 1).
Alternatively, differences in biological half-lives, tissue dis-
tribution, and/or cell permeability may explain the different
protective actions of 4 and 2 in septic mice. For instance, 1
penetrates into hepatocytes and comes out as 2 (28, 29).
Compound 4, on the other hand, has little tendency to cross the
cell membrane (30). Also, 2 has a half-life of several hours (31)
while the half-life of 4 is 1 h (unpublished data). Our results
showed that 4, which has a short half-life and low cell perme-
ability provided the best protection against the deleterious
effects of septic shock in mice.
It should be noted that iron chelators can interact with free
radicals produced in vivo (e.g. hydroxyl, superoxide). Thus,
oxygen-derived free radicals were implicated in the pathogen-
esis of endotoxemia, with the latter reduced in presence of 1
(32). Reactions of hydroxyl radical in vitro with 2, 1, 4 and the
Fe(II) complex of 3 have been described (33, 34), and catalytic
superoxide dismutase activity of 4 and DTPA-Fe(II) has been
shown (35). Several laboratories have recently reported hy-
droxamic acid-based metalloproteinase inhibitors of tumor
necrosis factor-a precursor processing to tumor necrosis fac-
tor-ca, which is implied in many inflammatory conditions.
However, the in vivo properties of these inhibitors, including
their ability to protect against septic shock, were not demon-
strated (36, 37). In addition, EDTA (at millimolar concentra-
tions), but not its zinc complex, was able to inhibit the tumor
necrosis factor-a-processing enzyme (38). This contrasted with
our results, wherein both iron complexes 2 and 4 exhibited
significantly better in vivo protective properties against septic
shock than their free-ligand forms 1 and 3, respectively.
Herein, we present in vitro evidence that iron chelators can
sequester and (as for 2) catalyze conversion of NO to benign
products. Demonstration of mechanistic aspects of septic
shock protection in vivo, including interaction with other free
radicals, may be hampered by the detection limits of current
analytical techniques. To detect the NO Fe-DETC complex
formation in livers of LPS-treated mice by the electron para-
magnetic resonance, it was necessary to apply a 500 mg/kg
dose of DETC (11). Our chelators demonstrated optimum
protection at 10 mg/kg, and at this low concentration it was not
possible to detect the electron paramagnetic resonance signal
of NO-iron-chelator in circulation or in the liver of C. parvum
+ LPS-treated mice. Nonetheless, our preliminary experi-
ments showed a decrease of the total NO-hemoglobin com-
plex formation in septic mice treated with 2 and septic baboons
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treated with 4. This observation is consistent with the in vivo
scavenging of NO by 2.
NO Binding by Iron Chelates: Electrochemical Studies. In
an attempt to determine the mechanism by which the iron
chelates scavenge NO, we investigated the chemistry of the
complexes with gaseous NO in aqueous solution using elec-
trochemical methods. We did not observe a reaction between
NO and either of the Fe(III) complexes, although both com-
plexes are known to undergo quasireversible reduction to
Fe(II) in solution, which is apparent in cyclic voltammograms
(39, 40). There are numerous reports of binding and reduction
of NO by Fe(II) generated chemically or electrochemically
(20-23, 41-43), which suggested to us that reduction of the
metal complexes to Fe(II) would provide in vivo NO scaven-
gers similar to those observed with other iron complexes (44,
45). The cyclic voltammogram of 4 (Fig. 2, solid line) shows a
quasireversible wave corresponding to the Fe(III/II) couple (E
- -0.22 V versus sodium chloride-saturated calomel elec-
trode). The reoxidation of Fe(II) back to Fe(III) was apparent
in buffer; however, once NO was introduced, the reoxidation
of Fe(II) disappeared (Fig. 2, dashed line), suggesting that the
Fe(II) complex forms an adduct with NO:
[Fe(III)(H2DTPA)] + e-4>[Fe(II)(H2DTPA)] [11
[Fe(II)(H2DTPA)]- + NO -* (Fe(II)(H2DTPA)(NO)]- [2]
Removal of NO by bubbling with nitrogen produced the









wave. The Fe(II)-NO adduct could be generated either by
reductive electrolysis of the Fe(III) complex in the presence of
NO or by the direct reaction of [Fe(II)(H2DTPA)]- with NO.
The IR spectrum of the adduct showed an NO stretch at 1778
cm-1, which agrees well with recent measurements on NO
adducts generated in situ (46). As expected for Fe(II) (32), this
frequency is consistent with formation of an adduct of neutral
NO radical rather than of NO' or NO-. The potential of the
Fe(III/II) couple for 4 is easily accessed by common biological
reductants (39, 47).
The electrochemistry of 2 (Fig. 3, solid line) is similar to that
of 4, except that the Fe(III/II) couple occurs at a much more
negative potential (E = -0.71 V, Fig. 3) (36, 37). As with the
DTPA complex 4, reduction to Fe(II) led to a reaction with
NO; however, this reaction was catalytic, producing the current
enhancement shown in Fig. 3 (short dashed line). This behav-
ior is indicative of NO binding by Fe(II) followed by further
reduction to produce a reduced form of NO and the regen-
erated 2 complex. As shown in Fig. 3, significant reductive
current for NO in the absence of the metal complex (long
dashed line) was not observed until a potential of about -0.65
V was reached; both this potential and that of the [Fe(III)-
(HDFB)]+ complex 2 are probably beyond the range of
common biological reductants (39, 47). However, in the pres-
ence of the catalyst, such as [Fe(III)(HDFB)]', significant NO
reduction current (Fig. 3, short dashed line) was observed at
potentials as low as -0.3 V, which is easily accessible in vivo.
Thus, in the absence of NO, 2 probably remains in the Fe(III)
state in vivo: however, in the presence ofNO, reduction of both
the metal complex and NO are feasible.
The [Fe(III)(HDFB)]+ complex2 is a remarkably stable and
efficient electrocatalyst. Both NO and NO- were excellent
substrates, and controlled potential electrolysis at Eapp < -0.5
V in the presence of either of these species resulted in an initial
increase in current to a steady-state level that remained
unchanged over many turnovers (Fig. 3 inset). In one exper-
iment, 16 equivalents of NO- were consumed with essentially
no change in current until the NO - was depleted. In a separate
experiment with excess NO-, 330 equivalents of charge were
passed through the solution and the steady-state current
remained at or above 70% of its maximum value. The overall
characteristics of the reaction were the same if electrolysis was
performed at -0.6 V, which corresponds to the potential of the
biological reductant NADPH (39, 47). Analysis of the gas in





FIG. 2. Cyclic voltammogram of [Fe(III)(H2DTPA)] 4 in 0.5 M
phosphate buffer at pH 7 with (dashed) and without (solid) NO.
Working electrode, glassy carbon; counter electrode, Pt wire; refer-
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FIG. 3. Cyclic voltammogram of [Fe(III)(HDFB)]+ 2 in 0.5 M
boric acid buffer at pH 8 with (short dashed) and without (solid) NO.
Also shown is the voltammogram of NO in the absence of metal
complex (long dashed). (Inset) Current-time profile observed during
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and that NO was generated as an intermediate when NO- was
used as the substrate.
Possible Mechanism of Septic Shock Protection by Iron
Complexes. The chemical studies suggested that 2 is a very
efficient NO scavenger that operates by catalyzing NO reduc-
tion at biologically relevant potentials. These results provide a
compelling stimulus for further design, synthesis, and evalua-
tion of compounds that bind and reduce nitric oxide via
transition-metal redox catalysis. Application of this newly
postulated mechanism to eradicate excessive levels of NO
could lead to novel treatments for diseases in which overpro-
duction of NO is a causative factor. Because 4 protected mice
against sepsis more effectively than 2, even though 2 operates
via a catalytic mechanism, the potential at which the iron
center is reduced may be a more important consideration than
the mechanism of NO scavenging. The DTPA complex 4 was
reduced at potentials well below those of many biological
reductants, while the DFB complex 2 was reduced at these
potentials only as a result of the catalytic mechanism (Fig. 3).
Nevertheless, these results suggest that a siderophore that
decomposes NO catalytically at a lower potential than DFB
might be a particularly effective NO scavenger and a prophy-
lactic for septic shock.
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